bluebird bio (BLUE) Stock Price, News & Analysis

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

12 equities research analysts have issued 12 month price objectives for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they expect the company's share price to reach $5.87 in the next twelve months. This suggests a possible upside of 475.5% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $1.38 on January 1st, 2024. Since then, BLUE stock has decreased by 26.1% and is now trading at $1.02.
View the best growth stocks for 2024 here.

bluebird bio saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 29,750,000 shares, a decrease of 12.6% from the March 15th total of 34,040,000 shares. Based on an average trading volume of 9,070,000 shares, the days-to-cover ratio is presently 3.3 days.
View bluebird bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company earned $12.40 million during the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The firm's revenue was up 17364.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.92) EPS.

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and Direxion Moonshot Innovators ETF (MOON).Horizon Kinetics Medical ETF (MEDX).

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Enterprise Bank & Trust Co (0.03%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima.
View institutional ownership trends.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.